Literature DB >> 8730838

Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat.

G Escames1, D Acuña Castroviejo, F Vives.   

Abstract

The excitatory response to motor cortex stimulation of 201 striatal neurones was recorded electrophysiologically to test the effects of melatonin (aMT) and/or D1 and D2 antagonists. Iontophoresis of aMT attenuated the excitatory response in 68.5% of neurones, with a latency of 2-4 min and enhanced the excitatory response in 11.9% of the neurones; 19.6% showed no change in response. Iontophoresis of sulpiride (D2 antagonist) produced an immediate increase in the excitatory response in 62.8% of neurones, an attenuation in 2.3% and no change in the response of 34.9%. The ejection of sulpiride counteracted the aMT-dependent inhibition of the excitatory response of striatal neurones. SCH-23390 (D1 antagonist) iontophoresis had no significant effect. The results show that the same striatal units may be driven by aMT and D2 receptors. However, the significant difference in the latency of the responses suggests that the effects of these two substances are mediated by different receptor/intracellular messengers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730838     DOI: 10.1097/00001756-199601310-00053

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 3.  Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting.

Authors:  N Zisapel
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

4.  Genetic deletion of MT(1) and MT(2) melatonin receptors differentially abrogates the development and expression of methamphetamine-induced locomotor sensitization during the day and the night in C3H/HeN mice.

Authors:  Anthony J Hutchinson; Randall L Hudson; Margarita L Dubocovich
Journal:  J Pineal Res       Date:  2012-06-07       Impact factor: 13.007

Review 5.  The Zebrafish, an Outstanding Model for Biomedical Research in the Field of Melatonin and Human Diseases.

Authors:  Paula Aranda-Martínez; José Fernández-Martínez; Yolanda Ramírez-Casas; Ana Guerra-Librero; César Rodríguez-Santana; Germaine Escames; Darío Acuña-Castroviejo
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

6.  Spike activity of neurons in the lateral hypothalamus in rats during microiontophoretic application of melatonin and noradrenaline.

Authors:  S S Pertsov; A F Meshcheryakov; R G Glushkov; K V Sudakov
Journal:  Neurosci Behav Physiol       Date:  2004-06

7.  Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure.

Authors:  Abla Benleulmi-Chaachoua; Alan Hegron; Marine Le Boulch; Angeliki Karamitri; Marta Wierzbicka; Victoria Wong; Igor Stagljar; Philippe Delagrange; Raise Ahmad; Ralf Jockers
Journal:  Cell Mol Life Sci       Date:  2018-07-24       Impact factor: 9.261

8.  Melatonin in Alzheimer's disease and other neurodegenerative disorders.

Authors:  V Srinivasan; S R Pandi-Perumal; D P Cardinali; B Poeggeler; R Hardeland
Journal:  Behav Brain Funct       Date:  2006-05-04       Impact factor: 3.759

Review 9.  Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease.

Authors:  Santiago Pérez-Lloret; Daniel P Cardinali
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 10.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.